Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem

Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE
The triplet combination of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is as good as dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in terms of efficacy for HIV control but results in better hepatitis B virus (HBV) outcomes in patients with HIV/HBV co-infection, according to results of the phase III ALLIANCE trial presented at IAS 2022.

Measuring patient-based changes in temperature could improve COVID-19 detection in nursing homes
Among nursing home residents, rather than using a one-size-fits-all threshold temperature, looking at individual changes in body temperature and temperature variability, could lead to better prediction of COVID-19 infection, a recent study has found.

Infusion-to-injection infliximab switch safe, helps lower risk of IBD relapse for some patients
Switching from intravenous to subcutaneous infliximab appears to be safe and well-accepted, resulting in a reduced risk of relapse in some inflammatory bowel disease (IBD) patients, according to data from the REMSWITCH study.

Relapse prevention interventions effective in MDD
In patients with remitted major depressive disorder (MDD), the use of psychological relapse prevention interventions, whether as a standalone or in combination with medication, effectively reduces the risk of relapse/recurrence, according to a recent meta-analysis.

Cholesterol, creatinine, platelet count tied to myocardial infarction, angina pectoris
Among the biochemical indices of obesity, cholesterol, creatinine, and platelet count appear to correlate with myocardial infarction or angina pectoris in both men and women, reports a recent study. Other indicators, including anthropometric measures, varied between sexes.

OASIS-1: Thumbs up for mirikizumab in moderate-to-severe plaque psoriasis
The interleukin (IL)-23 inhibitor mirikizumab demonstrates superior efficacy in the treatment of patients with moderate-to-severe plaque psoriasis as compared with placebo, with initial responses during induction preserved through the maintenance phase, according to the results of the phase III OASIS-1 trial.

FLT3 inhibitor improves survival in patients with FLT3+ acute myeloid leukaemia
Patients diagnosed with acute myeloid leukaemia with an FLT3 mutation (FLT3+ AML) may benefit from the addition of an FLT3 inhibitor to intensive chemotherapy postinduction by improving event-free (EFS) or overall survival (OS), suggests a study.

